Researchers at the University of Technology, Sydney have shown Comvita’s Medihoney® to have potent broad-spectrum antibacterial properties, including against some drug resistant varieties.
Findings published today, Friday 01 March, in the open-access science journal PLOS ONE highlight the benefits of combining Medihoney with the antibiotic rifampicin to treat skin and chronic wound infections. The research shows that a combinational use of Medihoney® and Rifampicin resulted in a synergistic effect against bacteria and prevented the development of bacterial resistance to rifampicin.
Medihoney® (Comvita NZ), a sterile medical-grade honey applied topically for wound and skin care has been commercially available for 14 years. A combination of physical characteristics and intrinsic antibacterial compounds account for the broad antibacterial activity seen in Medihoney®. Rifampicin, an antibiotic taken orally to treat Tuberculosis and skin infections, is often used in combination with other antibiotics as bacteria can develop resistance to it.
Commenting on the clinical significance of these findings, the authors noted that “this study highlights the potential of a combinational use of Medihoney and Rifampicin to develop novel therapies for chronic wounds and serious skin infections, to both improve efficacy and reduce the risk of antibiotic resistance”.
To learn more about Comvita’s MEDIHONEY® range click here
Synergism Between Medihoney and Rifampicin Against Methicillin-Resistant Staphylococcus aureus (MRSA)
Patrick Müller, Dagmar G. Alber, Lynne Turnbull, Ralf C. Schlothauer, Dee A. Carter, Cynthia B. Whitchurch and Elizabeth J. Harry.